Top

Supportive Care in Cancer

Published in:

01-02-2020 | Sarcopenia | Original Article

Cancer-related fatigue and biochemical parameters among cancer patients with different stages of sarcopenia

Authors: Bangyan Wang, Sudip Thapa, Ting Zhou, Huiquan Liu, Lu Li, Guang Peng, Shiying Yu

Published in: Supportive Care in Cancer | Issue 2/2020

Abstract

Purpose

Cancer-related fatigue (CRF) is a pervasive symptom experienced by cancer patients. Sarcopenia has been suggested as a treatment target of CRF. This study aims to assess the differences of CRF and biochemical markers among different stages of sarcopenia which remain poorly delineated.

Methods

A total of 187 patients were included in this cross-sectional study. Based on muscle mass (skeletal muscle index, SMI), muscle strength (handgrip strength), and physical performance (SARC-F score), patients were divided into four groups (non-sarcopenia, pre-sarcopenia, sarcopenia, and severe sarcopenia). Cancer-related fatigue was measured by the Brief Fatigue Inventory (BFI). Biochemical markers were measured by routine blood tests.

Results

The BFI score was significantly associated with sarcopenia stage (r=0.500; P<0.001). Cancer patients in severe sarcopenia group suffered from worse CRF than those in non-sarcopenia, pre-sarcopenia, and sarcopenia groups (P<0.001). In the multivariate linear regression model (R²=0.542), CRF was significantly correlated with SARC-F score (standardized B=0.519; P<0.001) and high-sensitivity C-reactive protein (standardized B=0.389; P=0.004). Serum albumin and cholinesterase were statistically correlated with both sarcopenia stage and CRF.

Conclusions

The significantly increased occurrence and severity of CRF in cancer patients with sarcopenia suggest that sarcopenia may be a crucial target to improve the management of CRF. Circulating albumin and cholinesterase have the potential to predicting sarcopenia as biomarkers.

Berger AM, Mitchell SA, Jacobsen PB, Pirl WF (2015) Screening, evaluation, and management of cancer-related fatigue: ready for implementation to practice? CA Cancer J Clin 65(3):190–211CrossRef

Minton O, Berger A, Barsevick A, Cramp F, Goedendorp M, Mitchell SA, Stone PC (2013) Cancer-related fatigue and its impact on functioning. Cancer 119(Suppl 11):2124–2130CrossRef

Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G (2013) Development of fatigue in cancer survivors: a prospective follow-up study from diagnosis into the year after treatment. J Pain Symptom Manag 45(2):213–222CrossRef

Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 5(5):353–360CrossRef

Glaus A, Crow R, Hammond S (1996) A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 4(2):82–96CrossRef

Mustian KM, Morrow GR, Carroll JK, Figueroa-Moseley CD, Jean-Pierre P, Williams GC (2007) Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist 12(Suppl 1):52–67CrossRef

Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini P, Stahl C, National Comprehensive Cancer Network (2000) NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 14(11a):151–161

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489–495CrossRef

Cohen S, Nathan JA, Goldberg AL (2015) Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov 14(1):58–74CrossRef

10.

Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31(12):1539–1547CrossRef

11.

Kim TN, Choi KM (2013) Sarcopenia: definition, epidemiology, and pathophysiology. J Bone Metab 20(1):1–10CrossRef

12.

Karthikeyan G, Jumnani D, Prabhu R, Manoor UK, Supe SS (2012) Prevalence of fatigue among cancer patients receiving various anticancer therapies and its impact on quality of life: a cross-sectional study. Indian J Palliat Care 18(3):165–175CrossRef

13.

Bower JE (2014) Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 11(10):597–609CrossRef

14.

Ahlberg K, Ekman T, Gaston-Johansson F, Mock V (2003) Assessment and management of cancer-related fatigue in adults. Lancet 362(9384):640–650CrossRef

15.

Neefjes ECW, van den Hurk RM, Blauwhoff-Buskermolen S, van der Vorst M, Becker-Commissaris A, de van der Schueren MAE, Buffart LM, Verheul HMW (2017) Muscle mass as a target to reduce fatigue in patients with advanced cancer J Cachexia Sarcopenia Muscle 8(4):623–629CrossRef

16.

Kilgour RD, Vigano A, Trutschnigg B, Hornby L, Lucar E, Bacon SL, Morais JA (2010) Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. J Cachexia Sarcopenia Muscle 1(2):177–185CrossRef

17.

Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, Heymsfield SB, Heshka S (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985) 97(6):2333–2338CrossRef

18.

Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krairit O, Lee JSW, Lee WJ, Lee Y, Liang CK, Limpawattana P, Lin CS, Peng LN, Satake S, Suzuki T, Won CW, Wu CH, Wu SN, Zhang T, Zeng P, Akishita M, Arai H (2014) Sarcopenia in Asia: consensus report of the Asian working group for Sarcopenia. J Am Med Dir Assoc 15(2):95–101CrossRef

19.

Malmstrom TK, Morley JE (2013) SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc 14(8):531–532CrossRef

20.

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M, European Working Group on Sarcopenia in Older People (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing 39(4):412–423CrossRef

21.

Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85(5):1186–1196CrossRef

22.

Wang XS, Hao XS, Wang Y, Guo H, Jiang YQ, Mendoza TR, Cleeland CS (2004) Validation study of the Chinese version of the Brief Fatigue Inventory (BFI-C). J Pain Symptom Manag 27(4):322–332CrossRef

23.

Butt Z, Rosenbloom SK, Abernethy AP, Beaumont JL, Paul D, Hampton D, Jacobsen PB, Syrjala KL, Von Roenn JH, Cella D (2008) Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Cancer Netw 6(5):448–455CrossRef

24.

de Raaf PJ, de Klerk C, van der Rijt CC (2013) Elucidating the behavior of physical fatigue and mental fatigue in cancer patients: a review of the literature. Psychooncology 22(9):1919–1929CrossRef

25.

Yavuzsen T, Davis MP, Ranganathan VK, Walsh D, Siemionow V, Kirkova J, Khoshknabi D, Lagman R, LeGrand S, Yue GH (2009) Cancer-related fatigue: central or peripheral? J Pain Symptom Manag 38(4):587–596CrossRef

26.

Neefjes EC, van der Vorst MJ, Blauwhoff-Buskermolen S, Verheul HM (2013) Aiming for a better understanding and management of cancer-related fatigue. Oncologist 18(10):1135–1143CrossRef

27.

Wagner LI, Cella D (2004) Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 91(5):822–828CrossRef

28.

al-Majid S, McCarthy DO (2001) Cancer-induced fatigue and skeletal muscle wasting: the role of exercise. Biol Res Nurs 2(3):186–197CrossRef

29.

Morgado PC, Giorlando A, Castro M, Navigante A (2016) Relationship between weight loss and parameters of skeletal muscle function in patients with advanced cancer and fatigue. Support Care Cancer 24(9):3961–3966CrossRef

30.

Kisiel-Sajewicz K, Davis MP, Siemionow V, Seyidova-Khoshknabi D, Wyant A, Walsh D, Hou J, Yue GH (2012) Lack of muscle contractile property changes at the time of perceived physical exhaustion suggests central mechanisms contributing to early motor task failure in patients with cancer-related fatigue. J Pain Symptom Manag 44(3):351–361CrossRef

31.

Bruera E, Brenneis C, Michaud M, Jackson PI, MacDonald RN (1988) Muscle electrophysiology in patients with advanced breast cancer. J Natl Cancer Inst 80(4):282–285CrossRef

32.

Paiva CE, Paiva BS (2013) Prevalence, predictors, and prognostic impact of fatigue among Brazilian outpatients with advanced cancers. Support Care Cancer 21(4):1053–1060CrossRef

33.

Temel JS, Pirl WF, Recklitis CJ, Cashavelly B, Lynch TJ (2006) Feasibility and validity of a one-item fatigue screen in a thoracic oncology clinic. J Thorac Oncol 1(5):454–459CrossRef

34.

Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, Mohr D, Palesh OG, Peppone LJ, Piper BF, Scarpato J, Smith T, Sprod LK, Miller SM (2017) Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 3(7):961–968CrossRef

35.

Goedendorp MM, Gielissen MF, Verhagen CA, Peters ME, Bleijenberg G (2008) Severe fatigue and related factors in cancer patients before the initiation of treatment. Br J Cancer 99(9):1408–1414CrossRef

Title: Cancer-related fatigue and biochemical parameters among cancer patients with different stages of sarcopenia
Authors: Bangyan Wang
Sudip Thapa
Ting Zhou
Huiquan Liu
Lu Li
Guang Peng
Shiying Yu
Publication date: 01-02-2020
Publisher: Springer Berlin Heidelberg
Keywords: Sarcopenia
Cancer Fatigue
Fatigue
Published in: Supportive Care in Cancer / Issue 2/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-04717-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

Aerobic exercise during chemotherapy infusion for cancer treatment: a novel randomised crossover safety and feasibility trial

Exploring the impact of providing men with information about potential prostate cancer treatment options prior to receiving biopsy results

An in-hospital clinical care pathway with integrated decision support for cancer pain management reduced pain intensity and needs for hospital stay

Response to Letter to the Editor: Improving information to caregivers of cancer patients: the Herlev Hospital Empowerment of Relatives through More and Earlier information Supply (HERMES) randomized controlled trial

Influence of health insurance status on childhood cancer treatment outcomes in Kenya

Perspectives from oncology patient navigation programs on information management practices and needs: a descriptive study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer